肺癌EGFR兩種常見突變：exon19缺失和L858R，治療反應為何不同？Two Common EGFR Mutations in Lung Cancer:Ex19 Deletion andL858R

肺癌中EGFR基因突變主要有兩種：exon19缺失和L858R。這兩種突變對於治療藥物的反應存在差異。造成這種差異的原因可能涉及基因構造的不同，進而影響抗癌藥物的結合及作用機制。深入研究突變的生物學特性有助於更有效地選擇和優化治療方案。

In lung cancer, EGFR gene mutations commonly include exon 19 deletion and L858R. These mutations exhibit different responses to treatment. The variations may be attributed to differences in genetic structures, affecting the binding and mechanisms of anticancer drugs. In-depth research into the biological characteristics of mutations contributes to more effective selection and optimization of treatment approaches.

腫瘤科醫師的生活點滴
臉書facebook：
https://m.facebook.com/profile.php/?id=100063644122566
Instagram：
https://instagram.com/chiaoenpeter?igshid=OGQ5ZDc2ODk2ZA==
加入頻道會員：
https://www.youtube.com/channel/UCBvUlnJq3TpnGtbV6fdnl2A/join
分享會員專屬影片：
https://www.youtube.com/playlist?list=UUMOBvUlnJq3TpnGtbV6fdnl2A